Author

W. Senkowski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

D. Bulanova· 2 shared J. Hynninen· 2 shared J. Oikkonen· 2 shared K. Wennerberg· 2 shared L. Gall-Mas· 2 shared S. Hautaniemi· 2 shared A. Vähärautio· 1 shared A. Virtanen· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Bulanova

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells

D. Bulanova, Y. Akimov, W. Senkowski, J. Oikkonen, L. Gall-Mas, S. Timonen, M. Elmadani, J. Hynninen, S. Hautaniemi, T. Aittokallio, K. Wennerberg

This study identifies CK2 inhibition as a sensitizing strategy for RB1-deficient ovarian and breast cancer cells to replication-perturbing drugs, showing enhanced efficacy when combined with existing therapies.

bioRxiv · Nov 14, 2022 · PreprintCancer Biology

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

W. Senkowski, L. Gall-Mas, M. M. Falco, Y. Li, K. Lavikka, M. C. Kriegbaum, J. Oikkonen, D. Bulanova, E. J. Pietras, K. Vossgröne, Y.-J. Chen, E. P. Erkan, M. K. Gronning Hog, I. M. Larsen, T. Lamminen, , K. Wennerberg

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

bioRxiv · Apr 21, 2022Cancer Biology